TNFRSF9 and cancer: In contrast, TAMs are potential biomarkers of immunotherapeutic responses in different cancer types.[48] We investigated the phenotype of TAMs, and the results showed that i.v. injection resulted in a higher frequency of M1‐type TAMs (17.38%) and significant infiltration of immune cells, such as CD4+ helper T cells (6.32%), CD8+ T cells (35.48%), Tc1 (13.00%), and 41BB+CD8+ T cells (27.18%), in tumor tissues (Figure 4I–N, Figure S13, Supporting Information).